ArticleFrontiers in veterinary science2024
Metabolomic profiling and antibacterial efficacy of probiotic-derived cell-free supernatant encapsulated in nanostructured lipid carriers against canine multidrug-resistant bacteria.
Article in Frontiers in veterinary science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biotechnological Potential of RhizosphericInternational journal of molecular sciences · 2026Article
- Insights into nanostructured lipid carriers for the effective delivery of bioactives in swine and poultry health: review.Animal bioscience · 2026Article
- Proteomic Analysis of the Differential Response ofAntibiotics (Basel, Switzerland) · 2025Article
- Isolation of porcine intestinal Lactobacillus salivarius and antimicrobial potential of its biosurfactant.BMC veterinary research · 2025Article
- Bioactive potential ofJournal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to investigate the antibacterial efficacy of probiotic-derived cell-free supernatants (CFS) encapsulated within nanostructured lipid carriers (NLCs) against multidrug-resistant Methods: Eight strains of lactic acid bacteria including Results: Despite the strong multidrug-resistant nature of the pathogens, CFS displayed a moderate antibacterial activity against most tested strains. The acidic nature of the CFS, combined with bioactive antibacterial metabolites like Kanzonol V and 1-Hexanol, likely contributed to its inhibitory effects against pathogenic bacteria; notably, Kanzonol V was abundant in the CFS of L22F, BF12 and BYF26 (L22F_CFS, BF12_CFS and BYF26_CFS), while 1-Hexanol was particularly enriched in CFS of P72N (P72N_CFS), with both compounds effectively targeting bacterial cell membranes to disrupt cell integrity, leading to bacterial cell death. Other beneficial compounds such as Pyroglutamylleucine, Trigoneoside VIII and 18-Nor-4(19),8,11,13-abietatetraene which are likely to have anti-inflammatory, antimicrobial and antioxidant activities, were also detected in the CFS. The CFS-NLCs maintained their antibacterial activity and 30-60% dilutions of product completely inhibited the growth of pathogen strains even after three-months storage at room temperature. Conclusion: These findings suggest that CFS-NLCs could be a promising biotic therapy for treating hospital infections such as canine dermatitis and otitis caused by multidrug-resistant
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.